Intercepting Cancer Earlier: Why Pharma Must Lead the Early Detection Agenda

• Reframing early detection as a strategic extension of drug development, not a departure from it
• Using ctDNA and emerging assays to guide earlier intervention, adjuvant decisions, and monitoring
• Aligning innovation with the ambition to eliminate cancer as a cause of death

Speakers:

Diana Vega

Global Senior Director, Early Detection

AstraZeneca